HK1207317A1 - 取代的 -萘啶 - Google Patents
取代的 -萘啶Info
- Publication number
- HK1207317A1 HK1207317A1 HK15108069.2A HK15108069A HK1207317A1 HK 1207317 A1 HK1207317 A1 HK 1207317A1 HK 15108069 A HK15108069 A HK 15108069A HK 1207317 A1 HK1207317 A1 HK 1207317A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- naphthyridines
- substituted
- Prior art date
Links
- 150000005056 1,6-naphthyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12193311 | 2012-11-20 | ||
PCT/EP2013/074012 WO2014079787A1 (en) | 2012-11-20 | 2013-11-18 | Substituted 1,6-naphthyridines |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1207317A1 true HK1207317A1 (zh) | 2016-01-29 |
Family
ID=47189816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15108069.2A HK1207317A1 (zh) | 2012-11-20 | 2015-08-20 | 取代的 -萘啶 |
Country Status (13)
Country | Link |
---|---|
US (1) | US9657014B2 (zh) |
EP (1) | EP2922540A1 (zh) |
JP (1) | JP2016505534A (zh) |
KR (1) | KR20150085538A (zh) |
CN (1) | CN104812387A (zh) |
AR (1) | AR093519A1 (zh) |
BR (1) | BR112015011094A2 (zh) |
CA (1) | CA2890685A1 (zh) |
HK (1) | HK1207317A1 (zh) |
MX (1) | MX2015006364A (zh) |
RU (1) | RU2015120217A (zh) |
TW (1) | TW201425312A (zh) |
WO (1) | WO2014079787A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI529171B (zh) | 2013-07-29 | 2016-04-11 | 赫孚孟拉羅股份公司 | 1,7-萘啶衍生物 |
US20160016951A1 (en) * | 2014-07-17 | 2016-01-21 | Merck Patent Gmbh | Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors |
WO2016128465A1 (en) * | 2015-02-11 | 2016-08-18 | Basilea Pharmaceutica Ag | Substituted mono- and polyazanaphthalene derivatives and their use |
SG11201706869XA (en) | 2015-03-24 | 2017-09-28 | Shanghai Yingli Pharm Co Ltd | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof |
WO2017079641A1 (en) * | 2015-11-06 | 2017-05-11 | Neurocrine Biosciences, Inc. | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases |
EA039638B1 (ru) * | 2016-01-06 | 2022-02-21 | Нейрокрин Байосайенсиз, Инк. | Антагонисты мускаринового рецептора 4 и способы их применения |
US20190390169A1 (en) | 2017-03-03 | 2019-12-26 | Kyoto University | Pancreatic progenitor cell production method |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9605437D0 (en) | 1996-03-15 | 1996-05-15 | Iaf Biochem Int | Cytomegalovirus inhibiting compounds |
US6255318B1 (en) * | 1997-12-11 | 2001-07-03 | Biochem Pharma Inc. | Antiviral compounds |
AU2002218902A1 (en) | 2000-12-27 | 2002-07-08 | Shire Biochem Inc. | Macrocyclic anti-viral compounds |
WO2006017672A2 (en) * | 2004-08-03 | 2006-02-16 | Serenex Inc. | 2, 8-disubstituted naphthyridine derivatives |
FR2904317A1 (fr) | 2006-07-27 | 2008-02-01 | Inst Nat Sante Rech Med | Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques |
US20080242694A1 (en) | 2006-09-18 | 2008-10-02 | D Sidocky Neil R | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith |
WO2008046072A2 (en) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Chemical inducers of neurogenesis |
SG172800A1 (en) * | 2009-01-19 | 2011-08-29 | Daiichi Sankyo Co Ltd | Heteroatom-containing cyclic compound |
WO2010101949A1 (en) * | 2009-03-02 | 2010-09-10 | Sirtris Pharmaceuticals, Inc. | 8-substituted quinolines and related analogs as sirtuin modulators |
NZ596154A (en) | 2009-04-06 | 2013-12-20 | Daiichi Sankyo Co Ltd | Cyclic compound having substituted phenyl group |
JP6126528B2 (ja) | 2010-07-07 | 2017-05-10 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムThe Board Of Regents Of The University Of Texas System | 神経新生促進化合物 |
JP2012036168A (ja) | 2010-07-15 | 2012-02-23 | Daiichi Sankyo Co Ltd | ヘテロ原子を有する環状化合物を含有する医薬組成物 |
-
2013
- 2013-11-18 EP EP13795705.6A patent/EP2922540A1/en not_active Withdrawn
- 2013-11-18 MX MX2015006364A patent/MX2015006364A/es unknown
- 2013-11-18 WO PCT/EP2013/074012 patent/WO2014079787A1/en active Application Filing
- 2013-11-18 CA CA2890685A patent/CA2890685A1/en not_active Abandoned
- 2013-11-18 KR KR1020157016208A patent/KR20150085538A/ko not_active Application Discontinuation
- 2013-11-18 CN CN201380060294.0A patent/CN104812387A/zh active Pending
- 2013-11-18 RU RU2015120217A patent/RU2015120217A/ru not_active Application Discontinuation
- 2013-11-18 AR ARP130104234A patent/AR093519A1/es unknown
- 2013-11-18 JP JP2015543399A patent/JP2016505534A/ja active Pending
- 2013-11-18 TW TW102141946A patent/TW201425312A/zh unknown
- 2013-11-18 BR BR112015011094A patent/BR112015011094A2/pt not_active IP Right Cessation
-
2015
- 2015-05-20 US US14/717,109 patent/US9657014B2/en not_active Expired - Fee Related
- 2015-08-20 HK HK15108069.2A patent/HK1207317A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20150252044A1 (en) | 2015-09-10 |
MX2015006364A (es) | 2015-10-05 |
CA2890685A1 (en) | 2014-05-30 |
CN104812387A (zh) | 2015-07-29 |
BR112015011094A2 (pt) | 2017-07-11 |
TW201425312A (zh) | 2014-07-01 |
WO2014079787A1 (en) | 2014-05-30 |
JP2016505534A (ja) | 2016-02-25 |
US9657014B2 (en) | 2017-05-23 |
RU2015120217A (ru) | 2017-01-10 |
KR20150085538A (ko) | 2015-07-23 |
EP2922540A1 (en) | 2015-09-30 |
AR093519A1 (es) | 2015-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1208443A1 (zh) | -苯並二氮雜䓬 | |
GB201304967D0 (en) | . | |
EP2935214A4 (en) | 1,4-PYRIDONES COMPOUNDS | |
GB201204183D0 (en) | . | |
HK1192757A1 (zh) | 取代的 -芳基- -苯基- -三嗪- -胺 | |
HK1207317A1 (zh) | 取代的 -萘啶 | |
HK1203974A1 (zh) | 抗-轉穀氨酰胺酶 抗體 | |
GB201214120D0 (en) | Yota 070812 | |
GB201222141D0 (en) | Further addtions 2 | |
TWM432338U (en) | M1010701_3919 | |
GB201220196D0 (en) | Magno-rebel 1 | |
GB201214054D0 (en) | Pakaging 0 | |
GB201207426D0 (en) | . | |
GB201206866D0 (en) | . | |
GB201206865D0 (en) | . | |
GB201205844D0 (en) | . | |
GB201208532D0 (en) | SockScreen 2 | |
GB201222887D0 (en) | The leo-scope | |
GB201206581D0 (en) | CityJaw 1830 | |
GB201222799D0 (en) | H.o.d | |
GB201200117D0 (en) | . | |
GB201200834D0 (en) | Vinsole 3 | |
GB201216334D0 (en) | The Quadbin | |
GB201200323D0 (en) | Easihang 45?/90? | |
GB201210424D0 (en) | Poop - pole N?2 |